GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » NeueHealth Inc (NYSE:NEUE) » Definitions » Peter Lynch Fair Value

NeueHealth (NeueHealth) Peter Lynch Fair Value : N/A (As of May. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeueHealth Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for NeueHealth's Peter Lynch Fair Value or its related term are showing as below:



NEUE's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Plans industry.
Industry Median: 1.55
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


NeueHealth Peter Lynch Fair Value Historical Data

The historical data trend for NeueHealth's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeueHealth Peter Lynch Fair Value Chart

NeueHealth Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

NeueHealth Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeueHealth's Peter Lynch Fair Value

For the Healthcare Plans subindustry, NeueHealth's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeueHealth's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, NeueHealth's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where NeueHealth's Price-to-Peter-Lynch-Fair-Value falls into.



NeueHealth Peter Lynch Fair Value Calculation

NeueHealth's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-14.345
=N/A

NeueHealth's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was $-14.35.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


NeueHealth  (NYSE:NEUE) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

NeueHealth's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=5.98/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeueHealth Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of NeueHealth's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


NeueHealth (NeueHealth) Business Description

Traded in Other Exchanges
N/A
Address
8000 Norman Center Drive, Suite 900, Minneapolis, MN, USA, 55437
Bright Health Group Inc is a technology-enabled, value-driven healthcare company focused on delivering affordable healthcare to the fast-growing aging and underserved populations in Florida, Texas, and California. It consists of two reportable segments: Bright HealthCare includes delegated senior managed care business that partners with a tight group of aligned providers in California focused on serving aging and underserved populations with unmet clinical needs through a Fully-Aligned Care Model, and Consumer Care includes a value-driven care delivery business that manages risk in partnership with external payors, It aims to significantly reduce the friction and current lack of coordination between payors by delivering on its Fully-Aligned Care Model with multiple payors.
Executives
Mikan George Lawrence Iii director, officer: CEO and President 200 SW 1ST AVE, SUITE 1600, FORT LAUDERDALE FL 33301
Jay Matushak officer: Chief Financial Officer C/O BRIGHT HEALTH GROUP, INC., 8000 NORMAN CENTER DRIVE, SUITE 900, MINNEAPOLIS MN 55437
Jeffrey S Cook officer: CEO, NeueHealth C/O BRIGHT HEALTH GROUP INC, 8000 NORMAN CENTER DRIVE SUITE 1200, MINNEAPOLIS MN 55437
Jeffrey J Scherman officer: Chief Accounting Officer C/O BRIGHT HEALTH GROUP, INC., 8000 NORMAN CENTER DRIVE, SUITE 1200, MINNEAPOLIS MN 55437
Cathy R Smith officer: CFO & CAO TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403
Jeff Michael Craig officer: GC & CORPORATE SECRETARY C/O BRIGHT HEALTH GROUP INC, 8000 NORMAN CENTER DRIVE SUITE 1200, MINNEAPOLIS MN 55437
Manuel Kadre director 2020 SALZEDO STREET, SUITE 301, CORAL GABLES FL 33134
Jeffrey R Immelt director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Nea 18 Vge Gp, Llc 10 percent owner C/O NEW ENTERPRISE ASSOCIATES, 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 18 Vge, L.p. 10 percent owner C/O NEW ENTERPRISE ASSOCIATES, 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 18 Venture Growth Equity, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Michael A Carson officer: CEO, Bright HealthCare C/O BRIGHT HEALTH GROUP INC., 8000 NORMAN CENTER DRIVE SUITE 1200, MINNEAPOLIS MN 55437

NeueHealth (NeueHealth) Headlines

From GuruFocus

Bright Health Group Appoints Jay Matushak as Chief Financial Officer

By Business Wire Business Wire 05-03-2023

Bright Health Group Receives Continued Listing Standard Notice from NYSE

By Business Wire Business Wire 12-12-2022